Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

Sponsor
Novo Nordisk A/S
Study ID
NCT00154401
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This trial is conducted in Europe. The trial is designed to show the effect of treatment with liraglutide or placebo on blood glucose control after 14 weeks in subjects with type 2 diabetes. Liraglutide or placebo is administered by injection once daily in the evening. The trial is a multi-national trial with treatment concealed to participating subjects, investigators and the sponsor. Treatment allocation is random with equal chance of being assigned to each group.

Key Dates

Start date
Jan 31, 2005
Status verified
Jan 2017
Primary completion
Oct 31, 2005
Completion
Oct 31, 2005

Study Design

Enrollment
177 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Primary Outcome Measure

HbA1c [ Time Frame: after 14 weeks treatment ]

Related Studies